Abstract
Introduction
Insulin resistance (IR) is defined as "a condition where a certain insulin concentration triggers a biological response lower than the normal one" [1, 2] .
Although IR is considered a fundamental disorder of type 2 Diabetes Mellitus (DM), its intervention in type 1 DM is more and more brought under discussion in the last period [1, 3, 4] , IR having also important implications in the onset and progression of micro-and macrovascular complications in type 1 DM [4, 5] . The gold standard of IR evaluation is represented by the method of euglycemichyperinsulinemic clamp [1, 6] , applied on a reduced scale and usually for research purposes [1, 6] . Therefore, it is necessary to identify less laborious markers for the assessment of IR in type 1 DM patients, markers which could be used on a large scale in current medical practice.
The suspicion of IR intervention in type 1 DM has started from the high variation of exogene insulin doses required to obtain the same degree of glycemic control in type 1 DM (from a low dose to doses over 2 UI/kg, and even higher) [6] .
The "accelerator hypothesis" as a unifier mechanism of type 1 and type 2 DM
The "accelerator hypothesis" was proposed by Wilkin (2001) as a unifier mechanism of type 1 and type 2 DM, representing two phenotype expressions of the same disease, the difference between them being made by the β-cells loss rate and by the presence of accelerators. Type 1 and 2 DM would actually be the same IR disease that emerges on a different genetic background [6] [7] [8] .
According to Wilkin, the three accelerators are: a high intrinsic rate of β-cells apoptosis, genetically determined [6, 7] ; overweight and IR, which increase the rate of β-cells apoptosis, thus accelerating the onset of type 1 and 2 DM [6, 7] ; and β-cells autoimmunity (in a small number of cases) -in the patients with accelerated apoptosis and IR, which increases the β-cells loss rate, diverting the pathological process towards type 1 DM [6, 7] .
But none of the accelerators leads to DM in the lack of overweight, which plays the main role in the increase of both types of DM incidence, by the exacerbation of IR [6] . Glucotoxicity directly accelerates apoptosis and, by inducing the β-cells imunogenes, it subsequently accelerates it towards a genetic subset prone to autoimmunity [6] . Body weight control, and implicitly control of IR, may represent the way of reducing the increase rate of DM incidence, in general [6] .
The epidemic increase of overweight and obesity makes it difficult to diagnose the type of DM, as IR and autoimmunity often coexist [9] [10] [11] . Some of the patients with type 1 DM have the disease onset at an adult age, with a quite slow evolution and without a tendency towards ketosis, or without any insulin requirement for years. On the other hand, type 2 DM can be also diagnosed in teenagers and young people, sometimes with ketoacidosis, the insulin dependence onset occuring after some time [7] . Thus, the notions of type 1 and 2 DM may be considered as artificial, as insulin dependence for the glycemic control is the final stage that all types of DM reach, sooner or later [7] , according to the concept of "β-cells loss time". The rate of β-cells loss determines the age of DM onset: never, in adulthood or childhood. Only time makes the difference between the childhood onset from the adulthood onset forms of DM [7] .
Arguments supporting the "accelerator hypothesis" in type 1 DM 2. IR acts in prediabetes, but there are great differences of prediabetes evolution towards type 1 DM. Probably the IR degree (increased during puberty or in obesity) is the one inclining the balance on one side or the other [6] .
3. IR also exists after the clinical onset of type 1 DM, an argument for this being the onset of the temporary remission ("honey moon") in type 1 DM, manifested by an important decrease of the exogenous insulin requirements. Some authors explain remission by the improvement of the endogenous insulin secretion as a consequence of the diminished pancreatic islands inflammatory reaction. Others state that there is a temporary improvement of the IR status present at diagnosis, namely the increase of tissular sensitivity towards insulin [6, 17] . The latter hypothesis seems more plausible since the C-peptide (having an equimolar secretion with insulin wich estimates the residual ß-cell function) measurement did not indicate any increase of its concentration during the oral glucose tolerance test (OGTT) or during other tests for insulin secretion stimulation, although the patients were in remission. Instead, the direct measurement of IR, through the euglycemichyperinsulinemic clamp method, confirmed that insulin sensitivity increases in those in remission, correlated with the necessary insulin dose and with HbA1c [6] . There are studies which showed that the "honey moon" end is accompanied by an increase in IR [6] .
4. Reduction of the insulin like growth factor-1 (IGF-1) concentration. IGF-1 is an important modulator of insulin sensitivity during puberty; it is synthesized in the liver, having insulin-like effects on glucose uptake in peripheral tissues and on hepatic glucose production. In type 1 DM, due to portal hypoinsulinemia, IGF-1 level is reduced, with a compensatory increase in the growth hormone (GH), which anatogonizes the insulin effects. The high seric levels of GH determine the synthesis of higher quantity of proteins binding IGF-1, thus decreasing the free seric IGF- HOMA-IR (C-peptide) = 1.5 + [fasting glycemia (mg/dl) x fasting C-peptide (ng/ml) /2800] HOMA-islet (C-peptide -Normal) = 0.27 x fasting C-peptide /(fasting glycemia -3.5) + 50 HOMA-islet (C-peptide -DM) = 0.27 x fasting C-peptide /( fasting glycemia -3.5) [32] .
It was shown that HOMA-IR (C-peptide) significantly correlates with HOMA-IR (r =0.689) while Homa-islet (C-peptide) significantly correlates with Homa-islet (r = 0.788); p = 0.000 [32] .
3. Fasting C-peptide Normal values of C-peptide are the following:
-children between 5 and 15 years oldfasting = 0.4 -2.2 ng/ml (mean 1 ng/ml); -adults -fasting = 0.4 -2.1 ng/ml (mean 1.1 ng/ml); -2 hours after meal = 1.2-3.4 ng/ml (mean 1.8 ng/ml ); -after 2 hours post load during the OGTT = 2-4.5 ng/ml (mean 3 ng/ml); -in urine: 20 nmol/24 hours (type 1 DM < 5 nmol/24 hours) [33] .
Conversion factors for C-peptide: 1 nmol/l=1 pmol/ml =3.9 ng/ml=3.9 µg/l [33].
In type 1 DM patients with a low but detectable C-peptide, the risk for renal and nervous complications is lower than in patients with absent C-peptide [33] . The combined treatment for 3 months with insulin and injectable C-peptide (600 nmol/24 h) improved renal function in patients with type 1 DM and incipient nephropathy, reducing the albumin urinary excretion (AUE), and also ameliorated autonomous and peripheral neuropathy in patients with type 1 DM [33,34], enhancing the cold-sensitivity threshold [33] .
Fasting C-peptide strongly correlated with known IR markers (HOMA-IR, QUICKI, insulinemia) in patients without DM. Thus, the subjects in the quartile with the highest Cpeptide (≥ 0.984 nmol/l) presented a 60% higher risk for cardiovascular mortality, and a 72% higher risk for all cause of mortality, compared to the subjects in the quartile with the lowest Cpeptide (≤ 0.418 nmol/l) [35] .
C-peptide is also a possible early biomarker for CVD in obese subjects, C-peptide exhibiting 4 significant correlations with other components of the MS (HDL-cholesterol, leptin, AC and uric acid), compared to insulinemia, which presented only 2 significant correlations (dBP and leptin) [36] . In this study [29] , eGDR was strongly correlated with IR measured by clamp (r = 0.79). The strongest inverse correlation with eGDR were HbA1c, WHR, AC and TG. There were also strong inverse correlation between eGDR and BMI and the daily insulin dose (U · kg The estimated IS score had a good correlation with GDR, both in young people with DM (also in young people with type 1 and 2 DM), as well as in the control young people, without DM. The IS score should be used with caution in children during puberty [26] .
The relation between the estimated IS score and fasting C-peptide in all the participants in the SEARCH study was a line of two spleen regression slopes with a loop in an IS score of 7.7 and a C-peptide level of 0.14 nmol/l [26] . 
Conclusions
All these evidences that support the role of IR in the onset and progression of micro-and macrovascular complications in type 1 DM should motivate clinicians and healthcare experts to prevent/reduce the epidemic of overweight and obesity in young people, which plays the main role in the onset of IR. Identification of markers for the assessment of IR in patients with type 1 DM, which could be used on a large scale in current medical practice, may help to reduce the large costs associated with the cronic complications of DM.
